Latest Ratios: P/E Ratio 11.0x · EV/EBITDA N/A · ROE 5.1%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $65M | $82M | $108M | $85M | $51M | $278M | $133M | $25M | $29M | $57M | — |
| Enterprise Value | $51M | $68M | $61M | $14M | $30M | $164M | $70M | $24M | $13M | $32M | — |
| P/E Ratio → | 10.99 | 17.01 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | 185.38 | 13.28 | 2.61 | — | — | — |
| P/B Ratio | 0.35 | 0.53 | 3.09 | 1.41 | 0.93 | 2.58 | 1.98 | 4.42 | 3.14 | 5.16 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | 109.08 | 7.01 | 2.47 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | 100.0% | 50.9% | 52.9% | — | — | — |
| Operating Margin | — | — | — | — | — | -2761.7% | -34.3% | -35.9% | — | — | — |
| Net Profit Margin | — | — | — | — | — | -2705.8% | -33.7% | -35.6% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.1% | 5.1% | -141.9% | -141.9% | -67.2% | -46.3% | -9.3% | -46.3% | -228.1% | -267.4% | — |
| ROA | 4.5% | 4.5% | -110.8% | -124.4% | -62.0% | -43.1% | -8.6% | -24.8% | -96.1% | -167.4% | -148.1% |
| ROIC | -43.0% | -43.0% | — | -545.5% | -308.3% | — | -59.5% | — | — | — | — |
| ROCE | -37.7% | -37.7% | -147.2% | -151.2% | -69.7% | -46.9% | -9.1% | -35.2% | -172.7% | -140.8% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 | 0.01 | 0.18 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | -1.34 | -1.17 | -0.37 | -1.06 | -0.94 | -0.24 | -1.77 | -2.32 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1522.50 | -1522.50 | — | — | -1007.31 | -989.51 | -88.13 | -151.13 | -1215.74 | -245.98 | -19.79 |
Net cash position: cash ($14M) exceeds total debt ($38000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 35.56 | 35.56 | 3.41 | 5.64 | 17.07 | 11.70 | 37.37 | 3.50 | 2.69 | 4.55 | 0.11 |
| Quick Ratio | 35.56 | 35.56 | 3.41 | 5.64 | 16.62 | 11.70 | 36.83 | 3.09 | 2.69 | 4.55 | 0.11 |
| Cash Ratio | 3.08 | 3.08 | 3.36 | 5.57 | 14.03 | 11.51 | 35.44 | 1.52 | 2.52 | 4.23 | 0.02 |
| Asset Turnover | — | — | — | — | — | 0.01 | 0.14 | 1.11 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | 5.03 | 7.06 | — | — | 0.83 |
| Days Sales Outstanding | — | — | — | — | — | 289.32 | 73.09 | 77.07 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 9.1% | 5.9% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $71M | $38M | $20M | $11M | $9M | $6M | $2M | $1M | $918858 | $939241 |
Includes 30+ ratios · 14 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LPTX stock.
Leap Therapeutics, Inc.'s current P/E ratio is 11.0x. The historical average is 17.0x.
Leap Therapeutics, Inc.'s return on equity (ROE) is 5.1%. The historical average is -96.4%.
Based on historical data, Leap Therapeutics, Inc. is trading at a P/E of 11.0x. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Imminent liquidity shortfall
Metrics are mathematically derived from official filings.
Distressed Valuation Reflects Clinical Uncertainty
Based on reported figures, LPTX trades at a P/B ratio of 0.35, a valuation level that suggests the market assigns minimal terminal value to the company's intangible clinical assets compared to the broader oncology biotechnology peer group, which often commands significantly higher premiums for late-stage pipeline candidates.
The current P/B multiple indicates that investors are pricing the company at a deep discount to its book value, likely reflecting skepticism regarding the clinical success of DKN-01 and the potential for further dilutive equity raises. This valuation gap suggests that the market is not currently assigning value to the pipeline's potential, but rather focusing on the immediate risk of capital depletion.
Negative Returns Underscore Capital Destruction
As reported in financial statements, LPTX's ROIC has remained consistently negative, reaching -3.3% in 2026Q1, which highlights the company's inability to generate productive returns on invested capital while it continues to consume cash to fund its ongoing clinical development programs and research initiatives.
The persistent negative ROIC is a structural reality for a pre-revenue biotech firm, but the trend suggests that the company is failing to achieve the efficiency gains necessary to justify its high R&D spend. Investors should monitor whether future clinical milestones can reverse this trend, as the current trajectory indicates significant value erosion for shareholders.
Liquidity Buffer Rapidly Approaching Exhaustion
According to recent SEC filings, the company's current ratio has fluctuated wildly, dropping from 35.56 in 2025Q4 to 27.28 in 2026Q1, a trend that masks the underlying reality of a rapidly depleting cash position that leaves the firm increasingly vulnerable to operational shocks.
While the current ratio appears high, it is a misleading metric for a company with minimal current liabilities but also negligible cash inflows. The rapid decline in absolute liquidity suggests that the company's ability to fund its clinical trials is nearing a critical inflection point, necessitating either a strategic partnership or a dilutive financing event.
Misapplication of P/E Multiples in Biotech
As indicated by the company's financial statements, the P/E ratio of 10.99 is a fundamentally flawed metric for LPTX, as it obscures the company's pre-revenue status and reliance on non-recurring accounting items rather than sustainable, core operational earnings from its oncology drug development pipeline.
Analysts should avoid using P/E multiples for LPTX, as they provide no insight into the company's clinical progress or its ability to reach commercialization. Instead, investors should focus on cash runway and the probability-weighted net present value of the DKN-01 asset, which are far more relevant to the company's actual business model.